Security record · archived quarter
SNDX
Syndax Pharmaceuticals, Inc. · Healthcare · Biotechnology
12Tracked holders
n/aΔ holders
17.35MShares held
$356.12MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 62.71K | $1.14M | n/a | −1 |
| Q2 2026 | 93 | 0 | 57.47M | $1.26B | +9 | −10 |
| Q1 2026 | 97 | +6 | 52.14M | $1.22B | +10 | −4 |
| Q4 2025 | 91 | -3 | 57.71M | $1.21B | n/a | −3 |
| Q3 2025 | 20 | +1 | 39.69M | $610.59M | +1 | n/a |
| Q2 2025 | 16 | +1 | 29.55M | $276.77M | +1 | n/a |
| Q1 2025 | 12 | -1 | 16.71M | $205.25M | n/a | −1 |
| Q4 2024 | 13 | +1 | 16.01M | $211.65M | +1 | n/a |
| Q3 2024 | 11 | -1 | 14.02M | $269.82M | n/a | −1 |
| Q2 2024 | 12 | n/a | 17.35M | $356.12M | n/a | n/a |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.34M | n/a | $150.67M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 2 | Point72 Asset Management ✦ | 2.78M | n/a | $57.13M | 0.2% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.91M | n/a | $39.23M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 1.83M | n/a | $37.58M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.07M | n/a | $21.87M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 930.95K | n/a | $19.11M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 860.00K | n/a | $17.66M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 214.30K | n/a | $4.40M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 189.98K | n/a | $3.90M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 146.64K | n/a | $3.01M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | T. Rowe Price ✦ | 48.20K | n/a | $990,000 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 27.27K | n/a | $559,915 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 244 holders, 99.11M shares, $2.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API